Hospital Pharmacy Europe

JULY 2, 2025

The UKPPLAB is actively discussing how it can build a sustainable and effective future model of pharmacy professional leadership in the light of the vote in favour of the proposals to establish the RPS as the Royal College of Pharmacy in 2026 and is encouraging pharmacy professionals to get in touch to share their views.

Patient Care 52

Patient Care Hospitals 52

PQA

APRIL 25, 2025

The application window for the 2026-27 fellow cycle will open in September. After graduating in May, Melody will further her commitment to pharmacy quality and innovation as the 2025-2026 Executive Fellow at PQA. PQA will welcome Melody Evans and Lauren Moy in June for the 2025-26 year. Learn more about her in this Q&A.

Specialty Pharmacies 52

Specialty Pharmacies Patient Care Hospitals 52

Hospital Pharmacy Europe

MAY 15, 2025

.’ Mr Badenhorst highlighted ‘a lack of clarity and consistent policy direction abouthowIPs are to be effectively and safely deployed’ He added: ‘The PDA believes that independent prescribing has enormous potential to enhance patient access, optimise medicines use, and relieve burden on GPs and hospitals.

Community Pharmacies 52

Community Pharmacies Hospitals Patient Care 52

Pharmacy Times

JUNE 27, 2025

Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. The recent application was granted both priority review and orphan drug designation. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.

FDA 56

FDA Compounding Pharmacies Immunization Chemotherapy 56

Pharmacy Times

JULY 21, 2025

Fournier, BSc Key Takeaways The 2024-2025 influenza season saw unprecedented severity, with high hospitalization and outpatient visit rates due to a vaccine mismatch and dominant H1N1 and H3N2 strains. 1 The US also reported the highest rates of hospitalizations and outpatient visits for flulike illnesses in 15 years.

Vaccines 117

Vaccines Immunization Hospitals Compounding Pharmacies 117

Pharmacy Times

JULY 26, 2025

1-4 About the Author Sinem Yasil is a 2026 PharmD candidate at the South College School of Pharmacy in Knoxville, Tennessee. Dabigatran is a direct thrombin inhibitor because it targets and inhibits factor IIa (thrombin) to achieve the same clinical effect. 5 A CBC provides information on an individual’s hematologic status.

Compounding Pharmacies 104

Compounding Pharmacies Vaccines Immunization Hospitals 104

Pharmacy Times

JUNE 4, 2025

USP plans to continue expanding its advanced technology footprint into an additional 8,000 square foot laboratory in 2026. The Advanced Technologies Lab is the latest of USP’s investments in advanced manufacturing technologies. Learn more about USP’s supply chain solutions.

Compounding Pharmacies 65

Compounding Pharmacies Compounding Immunization Specialty Pharmacies 65

Hospital Pharmacy Europe

JULY 9, 2025

The fast-track medical degree is due to open for applications via UCAS this September , with the first students enrolling in August 2026. Teaching will take place at partner hospitals, including Guy’s, King’s College and St Thomas’ Hospitals.

Hospitals 52

Hospitals Patient Care 52

European Pharmaceutical Review

JUNE 6, 2025

Dr Pakola shared that the trial is anticipated to support a Biologics License Application (BLA) submission for the gene therapy under accelerated approval in mid-2026. Top-line data is expected in H1 of 2026. “We are particularly encouraged by the outperformance observed in older patients”.

Hospitals 52

Hospitals 52

Pharmacy Times

JULY 4, 2025

SHOW MORE Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization. The research also demonstrated that no patients were hospitalized to treat their inflammatory condition during the study period.

Specialty Pharmacies 86

Specialty Pharmacies Hospitals Compounding Pharmacies Vaccines 86

Pharmacy Times

JULY 10, 2025

Relapse risk factors include prior hospitalizations, long illness duration, and antipsychotic polypharmacy, emphasizing the need for effective maintenance treatments. Maintaining stability in schizophrenia is a major clinical challenge—each relapse can disrupt functioning, burden caregivers, and elevate hospitalization risk.

FDA 50

FDA Hospitals Compounding Pharmacies Immunization 50

Pharmacy Times

JULY 24, 2025

6 A new drug application (NDA) with the FDA and global regulators are expected to be filed by March 2026, according to the manufacturers. Impressively, over 95% of trial completers entered the ongoing long-term extension study, reflecting both tolerability and sustained interest among participants.

Compounding Pharmacies 65

Compounding Pharmacies FDA Immunization Compounding 65

Drug Topics

JUNE 10, 2025

“RSV disease is the leading cause of infant hospitalization in the US and can lead to serious respiratory conditions like bronchiolitis and pneumonia,” Octavio Ramilo, an investigator on the CLEVER and SMART trials., said in a release.

FDA 430

FDA Vaccines Adverse Reactions Specialty Pharmacies 430

Pharmaceutical Commerce

JUNE 9, 2025

Image Credit: Adobe Stock Images/Artur.com Key Takeaways Sanofi is shipping Beyfortus early to ensure strong supply for the 2025–2026 RSV season and avoid past shortages. Beyfortus cut RSV hospitalizations by up to 83.2% Sanofi and AstraZeneca have tripled production capacity to meet growing demand. 3 References 1. June 9, 2025.

Vaccines 52

Vaccines Immunization Hospitals Pharmaceutical Companies 52

Drug Topics

JUNE 27, 2025

1,3 The day prior, ACIP took to discussions about COVID-1, which was highly awaited due to confusion surrounding the upcoming 2025-2026 respiratory season. 4 “The majority of children hospitalized with COVID-19 in October 2024 to March 2025 did not receive the most recently recommended COVID-19 vaccine,” he said. 4 REFERENCES 1.

Vaccines 405

Vaccines Independent Pharmacies Immunization Compounding 405

Pharmaceutical Technology

JULY 16, 2025

Anticipated next steps involve generating preclinical candidate data packages, which will include non-human primate studies expected in early 2026. Their efforts include exploring other oligomer-specific antibodies from Acumen’s library to identify potential lifecycle opportunities beyond sabirnetug alone.

Packaging 52

Packaging Communication Hospitals Insurance 52

Pharmaceutical Technology

JULY 18, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Pharmaceutical Companies 52

Pharmacy Times

JUNE 10, 2025

Some will assume roles in hospitals and health systems, long-term care, telehealth models, and other roles. Pharmacy schools are expected to graduate 8,000 student pharmacists in 2026…” [Instagram post]. 3,4 Now more than ever, we need additional PharmD graduates in the direct-to-career route. January 21, 2025. Accessed June 6, 2025.

Compounding Pharmacies 65

Compounding Pharmacies Hospitals Immunization Compounding 65

Pharmaceutical Technology

JULY 21, 2025

It is expected to enhance gross margin and contribute positively to operating income and earnings per share after 2026. July 21, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The acquisition of Blueprint provides Sanofi with a well-established foothold among allergists, dermatologists and immunologists.

Packaging 52

Packaging Communication Hospitals FDA 52

Pharmaceutical Technology

JULY 7, 2025

KalVista will receive an upfront payment of $11m, with an additional $11m contingent upon achieving a regulatory milestone anticipated by early 2026. In April 2025, KalVista Pharmaceuticals granted Kaken Pharmaceutical the commercialisation rights for sebetralstat in Japan. Sign up for our daily news round-up!

FDA 122

FDA Packaging Communication Hospitals 122

Pharmaceutical Technology

JULY 22, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

FDA 52

FDA Immunization Packaging Communication 52

Pharmaceutical Technology

JULY 21, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals FDA 52

Pharmaceutical Technology

JUNE 19, 2025

By GlobalData Learn more about Strategic Intelligence The company then plans to expand into a Phase Ib proof-of-concept trial in patients with KCNT1-related epilepsy in early 2026. The US Food and Drug Administration (FDA) has awarded ABS-1230 both orphan drug and rare paediatric designations.

Communication 52

Communication Hospitals Packaging Insurance 52

Pharmaceutical Technology

JULY 25, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals FDA 52

Pharmaceutical Technology

JULY 24, 2025

July 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Smouldering multiple myeloma represents an asymptomatic stage in the progression to multiple myeloma. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Insurance 52

Pharmaceutical Technology

JULY 23, 2025

July 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The focus of the investment is a manufacturing facility dedicated to producing drug substances for AstraZeneca. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Insurance 52

Pharmaceutical Technology

JULY 25, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Insurance 52

Pharmaceutical Technology

JULY 24, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Vaccines 52

Vaccines Packaging Communication Immunization 52

Pharmaceutical Technology

JUNE 18, 2025

Experts gathered at the ongoing BIO International Convention in Boston, US, this week were reasonably confident the programme will be reauthorised in a legislative package before its expiry in September 2026. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

FDA 59

FDA Packaging Communication Hospitals 59

Pharmaceutical Technology

JULY 1, 2025

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.

FDA 52

FDA Packaging Communication Hospitals 52

Pharmaceutical Technology

JULY 15, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Vaccines 52

Pharmaceutical Technology

JULY 23, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Communication 52

Pharmaceutical Technology

JULY 15, 2025

Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

Packaging 52

Packaging Communication Hospitals Vaccines 52

Pharmaceutical Technology

JUNE 19, 2025

As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026. These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options.

Communication 52

Communication Hospitals Packaging Compounding 52

Pharmaceutical Technology

JULY 14, 2025

A target action date of 28 April 2026 has been set under the Prescription Drug User Fee Act (PDUFA). The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for review to treat adults with virologically suppressed human immunodeficiency virus (HIV)-1.

FDA 52

FDA Packaging Hospitals Research Laboratories 52

Pharmaceutical Technology

JULY 14, 2025

A decision by the FDA is expected in H1 2026. GSK’s Arexvy is already approved in the US for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk. Give your business an edge with our leading industry insights.

Labelling 52

Labelling Vaccines FDA Packaging 52

Pharmaceutical Technology

JUNE 11, 2025

June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The company intends to introduce its inaugural product candidate into clinical trials by 2026. The company is progressing several programmes, intending to introduce its inaugural product candidate into clinical trials by 2026.

Communication 52

Communication Hospitals Packaging Insurance 52